Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
About
Adcendo ApS is a biopharmaceutical company focused on the development of first-and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need. The company is advancing a pipeline of novel ADCs designed to target specific cancer cells and deliver potent cytotoxic payloads, aiming to improve patient outcomes.
Tags
Total Employees
60
Current headcount
Performance
Company Timeline
No timeline data for this period
Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Adcendo do?
Adcendo ApS is a biopharmaceutical company focused on the development of first-and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need. The company is advancing a pipeline of novel ADCs designed to target specific cancer cells and deliver potent cytotoxic payloads, aiming to improve patient outcomes.
How much funding has Adcendo raised?
Adcendo has raised a total of $272M in funding. The most recent round on record is Series C.
Where is Adcendo headquartered?
Adcendo is headquartered in Copenhagen, Denmark.
When was Adcendo founded?
Adcendo was founded in 2017.
What industry does Adcendo operate in?
Adcendo operates in Biotechnology, Pharmaceuticals, Oncology, Drug Discovery, Biotech, MedTech.
How many employees does Adcendo have?
Adcendo has approximately 60 people on record.